MG
ELVN icon

Michael Gelband’s Enliven Therapeutics ELVN Stock Holding History

Michael Gelband’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,101
Closed -$1.18M – 1696
2026
Q1 		$1.18M Sell
30,101
-30,314
-50% -$840K 0.01% 949
2025
Q4 		$930K Buy
60,415
+12,280
+26% +$245K 0.01% 1022
2025
Q3 		$985K Buy
+48,135
New +$970K 0.01% 963
2025
Q2 		– Sell
-33,984
Closed -$669K – 1592
2025
Q1 		$669K Buy
33,984
+25,084
+282% +$540K 0.01% 1036
2024
Q4 		$200K Buy
+8,900
New +$231K ﹤0.01% 1364
2020
Q2 		– Sell
-4,957
Closed -$318K – 1831
2020
Q1 		$318K Buy
+4,957
New +$316K 0.02% 636

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Michael Gelband's ELVN Position: Q2 2026 in Review

Michael Gelband sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 30,101 shares — an estimated $1.18M sold.

Michael Gelband first reported a position in ELVN in Q1 2020 and held it in 6 quarters. The position peaked at $1.18M in Q1 2026. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Michael Gelband reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 30,101 Enliven Therapeutics shares in Q2 2026, an estimated $1.18M.
  • Michael Gelband first reported a position in Enliven Therapeutics in Q1 2020 and held it in 6 quarters.
  • Michael Gelband's Enliven Therapeutics position peaked at $1.18M in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.